A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer

The primary objective of this trial is to evaluate ovarian suppression following treatment with ZOLADEX 10.8 mg by luteinizing hormone (LH) within each cohort.

Trial Details

NCT ID
NCT07310420
Phase
PHASE1
Sponsor
TerSera Therapeutics LLC
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • ZOLADEX
Locations (sample)
  • Hot Springs, Arkansas, United States|34.5037,-93.05518
  • Washington D.C., District of Columbia, United States|38.89511,-77.03637
  • Ocoee, Florida, United States|28.56917,-81.54396
  • Athens, Georgia, United States|33.96095,-83.37794
  • Savannah, Georgia, United States|32.08354,-81.09983

Key Eligibility Criteria

  • Age and gender: Female participants aged 18 to 55 years, inclusive.
  • Hormone receptor positive (HR+): Either estrogen receptor positive (ER+) or progesterone receptor positive (PR+) breast cancer, defined as 1% to 10…
  • Participants must be of premenopausal status.
  • Recent radiotherapy:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →